Oragenics, Inc. (OGEN) Stock

Oragenics, Inc. (OGEN) is a Healthcare stock trading at $0.52 (as of 2026-08-21), with a market capitalization of $2.35M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Oragenics, Inc. is developing therapeutics for infectious diseases and other indications, including intranasal and intramuscular COVID-19 vaccine candidates (NT-CoV2-1 and Terra CoV-2), a weight loss candidate (LPT3-04), and a topical dental treatment (SMaRT Replacement Therapy). It also engages in collaborations and licensing arrangements related to these programs.

Understand Oragenics, Inc.: how it makes money

Oragenics develops antibiotics for infectious diseases and works on vaccine and therapeutic candidates, including NT-CoV2-1 and Terra CoV-2 (intranasal and intramuscular COVID-19 vaccine candidates) plus LPT3-04 (weight loss) and SMaRT Replacement Therapy (topical dental cavity prevention), with monetization expected through commercialization of these candidates.

Oragenics is a clinical-stage pipeline company, so the path to profit is largely determined by whether its product candidates progress to commercialization (vaccines and therapeutics), rather than by currently reported segment revenue.

Business quality (Weak): Clear product-candidate pipeline focus, but the provided data does not include reportable segments or operating KPIs, and the latest quarter shows 0.0 revenue with a very large negative operating margin.

Bull case

  • Product pipeline across multiple therapeutic areas: The company is developing multiple candidates, including NT-CoV2-1 and Terra CoV-2 (COVID-19 vaccines), LPT3-04 (weight loss), and SMaRT Replacement Therapy (topical treatment to prevent dental caries).
  • Both intranasal and intramuscular COVID-19 vaccine programs: It has an intranasal vaccine candidate (NT-CoV2-1) and an intramuscular vaccine candidate (Terra CoV-2) aimed at immunity from the novel severe acute respiratory syndrome coronavirus.

Bear case

  • No currently evidenced revenue in the latest quarter provided: For the period ended 2026-03-31, revenue is reported as 0.0B in the provided facts.
  • Significant operating losses indicated by operating margin: The latest provided operating margin is -5519.0%, indicating substantial operating losses.
  • High uncertainty typical of development-focused biopharma: The company’s business description emphasizes development and candidate programs, which face execution and clinical risk before commercialization.
Valuation — source: SEC EDGAR (first-party)
Price$0.52
Market Cap$2.35M
Price / Book0.64
Price / Sales13.06
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$182229.00
Net Margin-5401.2%
Revenue Growth (YoY)297.0%
EPS Growth (YoY)185.0%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderSABBY MANAGEMENT, LLC ($48355.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJanet Huffman
Employees3
CountryUS
IPO Date2004-02-25

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Ernexa Therapeutics Inc. (ERNA)
  • Nexentis Technologies Inc. (NXTS)
  • Onconetix, Inc. (ONCO)
  • HCW Biologics Inc. (HCWB)
  • CDT Equity Inc. (CDT)
  • Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
  • Jaguar Health, Inc. (JAGX)
  • Decoy Therapeutics Inc. (DCOY)
OGEN earnings history · OGEN institutional & insider holders · OGEN KPIs & operating metrics · OGEN financials · OGEN investor presentations & press releases · OGEN SEC filings · OGEN peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.